Balyasny Asset Management LLC Biocryst Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

$61.9 Billion
Q2 2025

A detailed history of Balyasny Asset Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 252,414 shares of BCRX stock, worth $1.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

252,414

Previous 586,206 56.94%

Holding current value

$1.75 Million

Previous $4.4 Million 48.57%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.41 - $11.19 $2.14 Million - $3.74 Million	-333,792 Reduced 56.94%	252,414 $2.26 Million
Q1 2025 May 15, 2025	BUY	$7.06 - $9.39 $399,264 - $531,032	56,553 Added 10.68%	586,206 $4.4 Million
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $3.72 Million - $4.46 Million	529,653 New	529,653 $3.98 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $7.79 Million - $10.6 Million	1,563,289 Added 382.88%	1,971,586 $11.8 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $2.74 Million - $3.23 Million	408,297 New	408,297 $2.89 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $315,175 - $432,600	29,210 Added 2.45%	1,223,721 $15.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $9.42 Million - $21.4 Million	1,194,511 New	1,194,511 $12.6 Million
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $5.71 Million - $16.9 Million	-3,005,676 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $4.81 Million - $12.4 Million	3,005,676 New	3,005,676 $6.01 Million
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $48,245 - $64,549	-11,091 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $177,652 - $227,617	-42,705 Reduced 79.38%	11,091 $54,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $220,563 - $321,162	53,796	53,796 $282,000

Others Institutions Holding BCRX

# of Institutions

314

Shares Held

201M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.29B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Biocryst Pharmaceuticals Inc Transaction History